Navigation Links
Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Date:10/23/2007

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

The Company also intends to host a conference call Wednesday, October 24, 2007 to provide an update on its expanding clinical program. The dial-in details appear below.

"We are really looking forward to treating patients in this trial," said Principal Investigator Dr. James Spicer. "The hope is that it will provide valuable information about the relationship between oncolytic viral therapy and the immune response of the patient."

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to stan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... YORK , Sept. 1, 2015 /PRNewswire-USNewswire/ ... of cancer death in American men. One ... cancer and 233,000 new cases are diagnosed annually. ... experts are using a powerful new technique, ... small and large cancer lesions, treating only the ...
(Date:9/1/2015)... ... September 01, 2015 , ... In her thought provoking debut novel ‘ ... a not-so-distant future faced with an Ebola pandemic that is on the cusp of ... to enter the world of counterterrorism, and who continues to appear in this series ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... , Equine cervical facet joint problems can be caused by injuries and ... cause impingement of nerve roots or of the spinal cord itself. This can ...
(Date:9/1/2015)... ... 01, 2015 , ... Leading CEOs, CSOs, CMOs, and heads ... join prominent academics and key investors for Neuro Advance Boston, October 14, 2015 ... , Neuro Advance Boston focuses on the latest developments and opportunities in ...
Breaking Biology Technology:September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2
... PRAIRIE, Minn., Oct. 7 ACIST Medical Systems,Inc., ... 75,000 square foot,expanded corporate Headquarters and manufacturing facility ... and Eden Prairie Mayor Phil Young will,join Fulvio ... a ribbon cutting,ceremony at the company,s new facilities. ...
... Calif., Oct. 7 Nektar,Therapeutics (Nasdaq: NKTR ) ... at the upcoming Natixis Bleichroeder Second Annual Hidden Gems,Conference ... October 13,2008 at 2:30 p.m. ET., The presentation ... the Investor Relations, Events Calendar section of the Nektar ...
... is a prominent expert on RNAi, delivery ... Paris, France, is foremost authority on bacterial ... Pharmaceuticals, a,pioneer in the development of novel products to ... that two of the,leading scientists in RNA Interference (RNAi) ...
Cached Biology Technology:ACIST Medical Systems Announces the Opening of Its New Expanded Corporate Headquarters in Eden Prairie, MN 2ACIST Medical Systems Announces the Opening of Its New Expanded Corporate Headquarters in Eden Prairie, MN 3Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D. 2Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D. 3
(Date:9/2/2015)... 2, 2015 Biometric ... in a system which uses identical human characteristic ... vein, DNA and finger print. Increasing number of ... such system which provides high level of security. ... and tokens are vulnerable to attacks. Furthermore, Biometric ...
(Date:8/28/2015)... , August 28, 2015 ... and Training Market by Assessment Type (Pen & Paper ... Brain Training, Corporate Learning, Academic Research), Vertical and Region ... Assessment and Training Market to grow from USD 2.4 ... at a Compound Annual Growth Rate (CAGR) of 25.6% ...
(Date:8/24/2015)... MOUNTAIN VIEW, Calif. , Aug. 24, 2015  Based ... & Sullivan recognizes DERMALOG with the 2015 African Biometrics Company ... manufacturer and has achieved substantial commercial success in ... Nigeria , where it has implemented one of ... equipped 23 banks as well as the Central Bank of ...
Breaking Biology News(10 mins):Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6
... food prices driven down by unprecedented advances in agricultural ... wheat have tripled and those for maize and rice nearly ... will fall soon. On the contrary, economists expect larger and ... and its devastating impacts on agriculture adding greatly to the ...
... ScD, Associate Professor of Surgery at the University of ... Hospital, has been awarded a $3 million grant from ... work in molecular cardiac surgery: a unique approach to ... four-year grant will enable Dr. Bridges to expand upon ...
... security market in EMEA spurs IdentiPHI,s company ... ... in enterprise security solutions and services, announces its,expansion with the opening of ... for identity and authentication (access,management) products and solutions., "Opening the office ...
Cached Biology News:Agriculture experts meet in Beijing to examine impacts of food prices and climate change on farmers 2Pennsylvania Hospital surgeon receives grant to develop molecular cardiac surgery 2Pennsylvania Hospital surgeon receives grant to develop molecular cardiac surgery 3IdentiPHI Opens Paris Office to Boost European Sales and Support 2
...
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
...
Biology Products: